Search Medical Condition
Please enter condition
Please choose location

Esophageal Cancer Clinical Trials

A listing of Esophageal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (296) clinical trials

Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial

Patients will be randomized to neo-adjuvant or adjuvant treatment. Quality of life questionnaires will be completed every 2 months up to 1 year.

Phase

Trial of Docetaxel Cisplatin Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)

Primary Objective: To establish the safety of combination chemotherapy comprising docetaxel (escalating doses: 25,30,35,40 mg/m2,day1 and day8), cisplatin (12mg/m2,day1-5), and fluorouracil (600mg/m2,day1-5) (DCF) in unresectable advanced esophageal cancer. Secondary Objective: To observe the efficacy of this regimen in these patients. Primary Objective: To assess the response rate of combination chemotherapy ...

Phase

A Study of Patients Receiving High-Dose Rate Brachytherapy

BACKGROUND High dose rate brachytherapy (HDR) is a challenging technique utilized in many malignancies in order to deliver a high dose of radiation therapy to a tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue HDR therapy has been targeted to ...

Phase

Photodynamic Therapy (PDT) Oncology Registry

Participating centers will need to describe its own mechanism for patient identification and eligibility screening. A data manager, identified by the Principal Investigator at each participating center, will screen all patients for eligibility. Appointment, diagnosis and treatment data will be reviewed using information such as clinic records, appointment lists, pathology ...

Phase N/A

Removal of the Evolution Esophageal Stent - Fully Covered

The CLARITY study is a clinical trial approved by US FDA to study the removal of the Evolution Esophageal Stent-Fully Covered in malignant and benign indications.

Phase N/A

Iron Replacement in Oesophagogastric Neoplasia

Anemia is a common problem to affect patients diagnosed with esophageal or gastric cancer. This anemia is thought to be secondary to blood loss from the tumor, poor oral intake resulting from symptoms of the tumor, and impaired iron absorption secondary to neoplasia induced inflammatory processes. Patients undergoing palliative chemotherapy ...

Phase

Esophageal Cancer Genetics Studies

The overall goal of this project is to understand the role of genetics in the etiology and prevention of upper gastrointestinal cancer, primarily esophageal cancer, but also cancers of the gastric cardia and body. Esophageal cancer is the fourth most common cause of cancer death in China and the seventh ...

Phase N/A

A clinical trial seeking patients for a research study for the treatment of Cellular aspects of, Cytology, gastrointestinal endoscopy, Gastric Cancer, Cytological Techniques, Esophageal Cancer, Esophagogastroduodenoscopy

Esophageal cancer is a common malignancy with a very poor prognosis. The principal reason for its poor prognosis is that most tumors are asymptomatic and go undetected until they have spread beyond the esophageal wall and are unresectable. Significant reduction in esophageal cancer mortality will require successful strategies to diagnose ...

Phase N/A

Combination Chemotherapy and Bevacizumab in Treating Patients With Recurrent Unresectable or Metastatic Gastric Cancer Gastroesophageal Junction Cancer or Esophageal Cancer

OBJECTIVES: Primary - Determine the efficacy of combination chemotherapy comprising modified docetaxel, cisplatin, fluorouracil, and leucovorin calcium with bevacizumab, as measured by 6-month progression-free survival (PFS), in patients with locally recurrent, unresectable, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. Secondary - Determine the safety of this regimen in these ...

Phase

Predicting Risk of Cancer in Barrett's Esophagus

Patients with Barrett's esophagus (BE) have an increased risk of esophageal adenocarcinoma which is 40-125 fold higher than in the general population. However, the current techniques of detecting dysplasia and observing abnormal p53 immunohistochemical staining are not accurate or reliable methods for determining which BE patients will progress to cancer. ...

Phase N/A